Marina Releases Data on miRNA Antagonists, Inks Deal for Up to $15M Investment | GenomeWeb

Marina Biotech this week announced that a microRNA inhibitor modified with the company's proprietary conformationally restricted nucleotide technology could trigger dose-dependent, in vivo de-repression of target genes.

Separately, the company said that it has signed a deal securing up to $15 million in equity capital from an institutional investor.

The CRN technology essentially comprises nucleotide analogs to which the C2' and C4' carbon bonds of the ribose ring are linked.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.